European advisory group backs expanded use of J&J’s Rezolsta

The European Medicines Agency’s advisory group CHMP has adopted a positive opinion recommending an expanded label for Johnson & Johnson (NYSE:JNJ) unit Janssen-Cilag International NV’s HIV med Rezolsta (darunavir/cobicistat) to now include adolescents as young as 12 years old (previously 18 years old) weighing at least 40 kg.

A final decision from the European Commission usually takes ~60 days.

https://seekingalpha.com/news/3536851-european-advisory-group-backs-expanded-use-of-j-and-js-rezolsta